New drug HRS-9813 aims to slow lung scarring in fibrosis patients
NCT ID NCT07192939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HRS-9813 in 270 adults with pulmonary fibrosis (IPF or PPF), a condition where lung tissue becomes scarred and breathing gets harder. The trial compares the drug to a placebo to see if it improves lung function and is safe. Participants take the drug or placebo for a period, and doctors measure breathing tests and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF AND PPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beyond the lungs: the hidden emotional toll of IPF medications
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Tracking lung scarring: new registry aims to map progressive pulmonary fibrosis in china
- Home devices may spot lung flare-ups before they become emergencies
- Small study tackles nasty side effect of lung drug